ProductHighlights:
TruSightTumor15usesnext-generationsequencing(NGS)technologytoprovideacomprehensiveassessmentof15genesthatarecommonlymutatedinsolidtumors.Itaccuratelydetectslow-frequencyvariantsfrom20ngofstartingDNAandisoptimizedforformalin-fixed,paraffin-embedded(FFPE)tumortissue.
ViewtheGeneList
Featuringarapidworkflowthatcanbeeasilyintegratedintolabprocedures,thispaneloffersasingleassayforaccurate,economical,andrapidanalysisofsolidtumors.
ThisTruSightTumorpaneloffers:
- Comprehensiveworkflow:Assess15geneswithonesimpleworkflowinsteadofsingle,iterativegenetestingwithpolymerasechainreaction(PCR)
- Efficient:Rapidturnaroundwithonly3.5hoursofhands-ontime,goingfromDNAtodatainapproximately36hours
- Relevantgenecontentforsolidtumors:Somaticvariantsselectedfromrelevantindustryguidelines1,2,keyopinionleaders3,4,andpharmaceuticalresearch
- SensitivevariantdetectionfromlowDNAinput:Accuratesomaticvariantdetectionof5%allelefrequencyusing20ngDNAfromFFPEtissuesamples
TruSightTumor15SampleDatasets
3humanreferencesamplesand5FFPE-exactedDNAsamplesfromlung,colon,melanoma,andbreasttumorswerepreparedusingTruSightTumor15.TheselibrariesweresequencedontheMiniSeqSystemusingahighoutputkitata2x150bpreadlengthconfigurationwithdualindexing.Thetotalyieldwas7.6Gbwith94.9%ofbasesatoraboveQ30.
BrowsethedatainBaseSpaceSequenceHub:
- ViewRun
- ViewProject
AccesstothisdatarequiresaBaseSpaceSequenceHublogin.
RegisterforBaseSpaceSequenceHub
Specifications:
| AssayTime | 7hours |
| Hands-OnTime | 3.5hours |
| InputQuantity | 20ng |
| SystemCompatibility | MiSeq,MiSeqDxinResearchMode,MiniSeq |
| SpecializedSampleTypes | FFPE,LowInput |
| Technology | Sequencing |
| VariantClass | SomaticVariants,Insertions-Deletions(indels) |
| SpeciesCategory | Human |
| CancerType | SolidTumor |
| Method | AmpliconSequencing,TargetedDNASequencing |
